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Abstract
Purpose—Activating PIK3CA genomic alterations are frequent in head and neck squamous cell 
carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (PI3K) 
signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting PI3K 
with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination with 
radiation in HNSCC.
Experimental Design—The efficacy of GDC-0032 was assessed in vitro in 26 HNSCC cell 
lines with crystal violet proliferation assays, and changes in PI3K signaling were measured by 
Western blot analysis. Cytotoxicity and radiosensitization were assessed with Annexin V staining 
via flow cytometry and clonogenic survival assays, respectively. DNA damage repair was assessed 
with immunofluorescence for γH2AX foci, and cell cycle analysis was performed with flow 
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cytometry. In vivo efficacy of GDC-0032 and radiation was assessed in xenografts implanted into 
nude mice.
Results—GDC-0032 inhibited potently PI3K signaling and displayed greater antiproliferative 
activity in HNSCC cell lines with PIK3CA mutations or amplification, whereas cell lines with 
PTEN alterations were relatively resistant to its effects. Pretreatment with GDC-0032 
radiosensitized PIK3CA-mutant HNSCC cells, enhanced radiation-induced apoptosis, impaired 
DNA damage repair, and prolonged G2–M arrest following irradiation. Furthermore, combined 
GDC-0032 and radiation was more effective than either treatment alone in vivo in subcutaneous 
xenograft models.
Conclusions—GDC-0032 has increased potency in HNSCC cell lines harboring PIK3CA-
activating aberrations. Further, combined GDC-0032 and radiotherapy was more efficacious than 
either treatment alone in PIK3CA-altered HNSCC in vitro and in vivo. This strategy warrants 
further clinical investigation
Introduction
Radiotherapy is the primary local treatment used for head and neck squamous cell 
carcinomas (HNSCC) arising from many anatomic sites, including the oropharynx, 
hypopharynx, nasopharynx, and larynx. Concurrent administration of cisplatin-based 
chemotherapy has been shown to improve overall survival in patients with locally advanced 
HNSCC undergoing definitive radiation, primarily by decreasing locoregional relapse (1). 
However, concurrent chemotherapy also significantly increases toxicity during, and possibly 
after, radiotherapy (2–5). In addition to cisplatin, the anti-epidermal growth factor receptor 
(EGFR) monoclonal antibody cetuximab has also been shown to improve overall survival 
and locoregional progression-free survival, without increasing acute or late radiation 
toxicity, when administered concurrently with radiation (6). Despite this success, EGFR 
inhibitor–based radiation regimens may be less effective than platinum-based 
chemoradiation (7). Therefore, novel agents that radiosensitize HNSCC in a tumor specific 
manner continue to be sought.
The most common oncogenic alteration in HNSCC is the aberrant activation of PI3K via 
mutations or amplification of PIK3CA, the gene encoding the α-isoform of catalytic subunit 
of PI3K (p110α; refs. 8–12). According to The Cancer Genome Atlas (TCGA ref 13), 
activating PIK3CA alterations are present in 56% and 34% of HPV+ and HPV− HNSCCs, 
respectively. Activation of PI3K leads to synthesis of phosphatidylinositol 3,4,5-
trisphosphate (PIP3) at the plasma membrane that, in turn, leads to the recruitment of the 
pleckstrin homology domain–containing proteins phosphoinositide dependent protein 
kinase-1 (PDK1) and AKT. PDK1 phosphorylates AKT at threonine 308 and activates AKT 
and downstream signaling elements, including mammalian target of rapamycin (mTOR) 
complex 1 (mTORC1), thereby promoting cell growth, proliferation, survival, and 
angiogenesis and regulating glucose metabolism (14).
The PI3K signaling axis is an attractive target for inducing tumor-specific radiosensitization 
for a variety of reasons. DNA damaging agents, including radiation, induce phosphorylation 
of AKT, both at threonine 308 and serine 473, and activate downstream signaling within 
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minutes of treatment (15–18). We and others have demonstrated that inhibition of PI3K or 
knockdown of PIK3CA enhances DNA damage and sensitizes breast cancer cells to PARP 
inhibition (19, 20). Furthermore, inhibition of PI3K–AKT–mTOR signaling has been shown 
to sensitize cancer cells to radiation-induced cytotoxicity (15, 16, 21–24). A major caveat of 
these previous studies was their reliance on nonspecific PI3K inhibitors such as wortmannin 
(25), LY294002 (26), and NVP-BEZ-235 (27), which also have potent inhibitory activity 
against PI3K-like kinases (PIKK) such as DNA-PKcs, ATM, and ATR, enzymes that play a 
central role in the repair of DNA damage following radiation. Thus, it is difficult to ascertain 
from these studies the relative contributions of PI3K inhibition, as opposed to PIKK 
inhibition, on the radiation-enhancing effects reported.
Recently, several isoform-specific PI3K inhibitors have been developed and have entered 
into early-phase clinical trials (28, 29). One of them, GDC-0032, is a potent inhibitor of 
p110α, p110δ, and p110γ, but with 31 times less potency for the remaining class IA PI3K 
enzyme p110β. Additionally, GDC-0032 is over 1,000 times more selective for p110α than 
any tested PIKK, including no significant inhibitory activity against DNA-PKcs (30). 
GDC-0032 has shown clinical activity in tumors harboring PIK3CA alterations in early 
clinical trials, including in head and neck cancer (29). We thus decided to investigate the 
efficacy of GDC-0032 in HNSCC, both as a single agent and in combination with 
radiotherapy with the goal to determine whether further clinical development of this class of 
agents is warranted in this disease.
Materials and Methods
Reagents
GDC-0032 was provided by Genentech. For in vitro assays, all drugs were dissolved in 
dimethyl sulfoxide. For in vivo experiments, GDC-0032 was dissolved in sterile water, 0.5% 
methyl-cellulose, and 0.2% Tween-80.
Cells and cell culture
All HPV-negative cells were obtained directly from the American Type Culture Collection 
(Cal-33, FaDu, Detroit 562, SCC-4, SCC-9, SCC-15, and SCC-25), the European Collection 
of Cell Cultures via Sigma-Aldrich (BICR-16, BICR-18, BICR-22, and BICR-31), the 
Japanese Collection of Research Bioresources (HSC-2, HSC-3, and HSC-4), or the Korean 
Cell Line Bank (SNU-46, SNU-1076, SNU-1214, and YD-8), with the exception of LB-771, 
which was obtained from The Center for Molecular Therapeutics at Massachusetts General 
Hospital. The HPV-positive cell lines UD-SCC-2, UM-SCC-47, UPCI-SCC-90, and 93-
VU-147T were kind gifts from the Paul Harari lab at the University of Wisconsin (Madison, 
WI). UM-SCC-104 was purchased from the lab of Thomas Carey at the University of 
Michigan (Ann Arbor, MI), and UPCI-SCC-154 was purchased from the Leibniz Institute 
DSMZ-German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). 
All cell lines were maintained in humidified incubators at 37°C in Dulbecco's modified 
Eagle's medium/Ham's F-12 1:1, with the exception of SNU-1076, SNU-46, SNU-1214, and 
YD-8, which were grown in RPMI-1640. Cell culture media were supplemented with 10% 
Zumsteg et al. Page 3
Clin Cancer Res. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, penicillin (20 U/mL), and 
streptomycin (20 μg/mL).
Determination of PIK3CA mutation and copy number status
PIK3CA mutation and amplification status information for each cell line was obtained from 
the Cancer Cell Line Encyclopedia (www.broadinstitute.org/ccle; ref. 31), except for 
LB-771 and the six HPV-positive cell lines, which were sequenced using the MSK-IMPACT 
next-generation sequencing platform (32). Amplification was defined as greater than or 
equal to 4 copies of the PIK3CA gene.
Proliferation assays
Cells were seeded in replicates of 6 in 96-well plates with 500 to 5,000 cells/well overnight 
and then treated with GDC-0032. After 4 days, the media were removed and the cells were 
fixed with 4% glutaraldehyde for 30 minutes. Fixed cells were stained with 0.1% crystal 
violet for 2 minutes, then washed, and dissolved in 10% acetic acid. Absorption of light was 
quantified using a Biotek Synergy H1 plate reader.
Clonogenic survival assays
Cells were plated in 6-well plates in appropriate dilutions (37, 111, 333, 1,000, 3,000, or 
9,000 cells/well) and allowed to attach overnight. Cells were then treated with DMSO or 
drug for 24 hours and irradiated at various dosing using a cesium irradiator. Drugs were left 
in following irradiation. Ten to 14 days after irradiation, cells were fixed with 4% 
glutaraldehyde and stained with 0.1% crystal violet. Colonies with greater than 50 cells were 
counted. Surviving fractions were calculated by normalizing to the plating efficiency at 0 Gy 
for either control- or drug-treated plates.
Western blot analysis
Cells were washed twice in ice-cold phosphate-buffered saline, scraped from the plate, 
centrifuged, and then frozen at −20° C after the supernatant was removed. The cells were 
then lysed in ice-cold radioimmunoprecipitation buffer supplemented with phosphatase 
inhibitor cocktails (Complete Mini and PhosphoStop, Roche), centrifuged, and the 
supernatant was removed for protein quantification (Pierce BCA Protein Assay Kit, Thermo 
Scientific). Twenty-five to 50 μg of protein was loaded into NuPAGE 4% to 12% bis–tris 
gels (Life Technologies) and resolved via electrophoresis, then transferred to Immobilon 
transfer membranes (Millipore). Membranes were blocked in 5% BSA in TBS-T for 1 hour 
prior to overnight incubation in primary antibody at 4°C, and incubated in either mouse or 
rabbit horseradish peroxidase–conjugated secondary antibodies (1:50,000; Amersham 
Biosciences) in 2% BSA in TBS-T for 1 hour. Membranes were imaged using SuperSignal 
West Femto Chemiluminescent Substrate (Thermo Scientific) and images were captured 
using a GBOX camera system. Antibodies used are listed in Supplementary Table S1.
Immunofluorescence
Cells were seeded into 8-chamber culture slides (BD Falcon), fixed at each time point with 
4% formaldehyde at room temperature, and then rinsed with PBS and stored in PBS at 4°C 
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Cells were permeabilized with 0.8% Triton X-100 and 0.2% BSA in PBS for 10 minutes on 
ice and then blocked with 1% BSA in TBS-T for 1 hour at room temperature, followed by 
incubation with γH2AX (1:500; Millipore) and 53BP1 (1:200; Bethyl) antibodies in 1% 
BSA in TBS-T for 2 hours at room temperature. The cells were then washed with TBS-T 
and incubated with Alexa 555 anti-rabbit and Alexa 488 anti-mouse secondary antibodies 
(both 1:1,000; Life Technologies) at room temperature. The cells were washed with TBS-T, 
rinsed in ddH20, and coverslipped with ProLong with DAPI (Life Technologies). Slides 
were digitally scanned with a Pannoramic Flash scanner (3DHistech) using 20×/0.8NA 
objective. The images were then analyzed using Metamorph software (Molecular Devices); 
briefly, nuclear regions were segmented using the DAPI channel, and the number of foci was 
counted using spot detection.
Annexin V staining
Cells were treated with either GDC-0032 or DMSO for 24 hours, irradiated or mock-
irradiated, then trypsinized and harvested along with cells in the media after an additional 72 
hours. Cells were resuspended in Annexin V buffer, stained with Annexin V–FITC and 
propidium iodide (PI) according to the manufacturer's instructions (BD Biosciences), and 
analyzed for fluorescence with a Fortessa flow cytometer. Resulting data were analyzed 
using FlowJo software.
Cell-cycle analysis
Cells were collected by trypsinization, washed in ice cold PBS, resuspended in 70% ethanol 
and stored at −20°C for at least 2 hours. Ethanol was then removed, cells were washed in 
wash buffer (1% BSA, 0.25% Triton X-100, and 2.5 mmol/L EDTA in PBS), then incubated 
in wash buffer containing 40 μg/mL PI (Sigma) and 100 μg/mL RNase A (Sigma) for 20 
minutes. Cells were characterized for fluorescence with either a FACSCalibur or a Fortessa 
flow cytometer, and the resulting distributions were analyzed using FlowJo software.
In vivo xenograft studies
All in vivo studies were conducted according to the Memorial Sloan Kettering Research 
Animal Resource Center-approved protocols and Johns Hopkins University Animal Care 
and Use Committee approved protocols. Six-week-old Nu/Nu mice were order from Harlan 
Laboratories. For cell line-derived xenograft studies, mice were injected bilaterally with 5 × 
105 cells resuspended in 200 μL of culture media and Matrigel (BD Biosciences) mixed in a 
1:1 ratio. After tumors reached approximately 100 to 200 cm3, mice were randomized into 
treatment arms with 8 to 10 tumors per group. GDC-0032 (5 mg/kg) was dissolved in a 
vehicle containing 0.5% methylcellulose with 0.2% TWEEN-80 and was administered via 
daily oral gavage. Tumors were irradiated using an X-RAD 320 X-ray system with 
appropriately sized lead shields.
For patient tumor–derived xenograft studies, mice were implanted with a tumor obtained 
from a patient with oropharynx squamous cell carcinoma. The tumor DNA was sequenced 
using CancerSelect-203 R platform (Personal Genome Diagnostics) and found to have a 
PIK3CAE542K mutation. After tumors reached approximately 100 to 250 cm3, mice were 
randomized into treatment arms with 5 to 6 tumors per group. GDC-0032 (5 mg/kg) was 
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administered via daily oral gavage for 14 days. Tumors were irradiated 2 Gy daily on days 2 
to 4 using a Small Animal Radiation Research Platform at the Johns Hopkins University. 
Tumor volumes were calculated as (π/6) × length × width2.
Results
GDC-0032 is active in HNSCC cell lines harboring activating PIK3CA aberrations and wild-
type PTEN
We tested the antiproliferative activity of GDC-0032 across a panel of 26 HNSCC cell lines, 
including the majority of commercially available HPV-positive HNSCC cell lines. As 
expected, there was a gradient of sensitivity in HNSCC cell lines. Cell lines harboring either 
mutations or amplification of PIK3CA tended to be sensitive to GDC-0032, with IC50 values 
in the nanomolar range (Fig. 1A). In contrast, 4 of the 6 most resistant cell lines to 
GDC-0032 had mutation or loss of PTEN, consistent with previous reports of PTEN 
aberrations leading to resistance to PI3Kα inhibitors through upregulation of PI3Kβ 
signaling (33–35). The observation of a preferential antiproliferative effect of GDC-0032 in 
cells with activated PI3KCA has also been observed with other isotype-specific PI3K 
inhibitors in other tumor types, suggesting that this selectivity could be important in the 
clinic (36, 37). In contrast, neither PIK3CA nor PTEN status correlated with sensitivity to 
GDC-0941, a pan-PI3K inhibitor with similar potency against all class IA PI3K isoforms 
(Fig. 1B). Thus, although PIK3CA and PTEN status may help identify tumors sensitive to 
GDC-0032, this is not a property shared amongst all classes of PI3K inhibitors.
GDC-0032 induces apoptosis in cell lines with PIK3CA alterations
Next, we investigated the effects of GDC-0032 on downstream PI3K signaling in several 
genetic contexts. Treatment with GDC-0032 in Cal-33 cells (harboring a PIK3CAH1047R 
mutation) prevented phosphorylation of AKT and inhibited downstream mTOR targets, such 
as ribosomal protein S6 kinase (S6K), eukaryotic translation initiation factor 4E-binding 
protein 1 (4EBP-1), and S6 (Fig. 2A). This translated into an induction of apoptosis, as 
assessed by cleavage of poly-ADP ribose polymerase (PARP). Similar results were obtained 
in LB-771, a cell line containing amplification of PIK3CA (Supplementary Fig. S1A). In 
cell lines containing either PTEN homozygous deletion (UD-SCC-2) or mutation (UPCI-
SCC-90), GDC-0032 was appreciably less effective at downregulating AKT/mTOR 
signaling and inducing cell death (Fig. 2A and Supplementary Fig. S1B). This supports the 
notion that downregulation of PI3K signaling is necessary for the proapoptotic effects of 
GDC-0032 in HNSCC.
The dose of 100 nmol/L GDC-0032, which inhibits AKT/mTOR signaling in PIK3CA 
mutant cell lines but not in cells with loss or mutation of PTEN, was chosen for subsequent 
time-course experiments. This dose of GDC-0032 inhibited phosphorylation of AKT and 
downstream signaling in Cal-33 (PIK3CA mutant) and LB-771 (PIK3CA amplified) cells, 
but had little effect on PI3K signaling in UD-SCC-2 (PTEN homozygous deletion) or UPCI-
SCC-90 cells (PTEN mutant; Fig. 2B), confirming that this is a concentration of GDC-0032 
that inhibits PI3Kα- but not PI3Kβ-dependent signaling.
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GDC-0032 radiosensitizes cells with PIK3CA mutation/amplification
Given that inhibition of PI3K signaling has been purported to affect expression of DNA 
damage repair (DDR) proteins (19, 20, 38) and alter DDR signaling in response to radiation 
(15, 17), we next sought to study the effect of GDC-0032 on HNSCC cell lines treated with 
radiation. In Cal-33 cells (PIK3CAH1047R), the combination of GDC-0032 and radiation 
resulted in both more apoptotic (Annexin V–positive, PI-negative) and nonapoptotic 
(Annexin V–positive, PI-negative) cell death than either treatment alone (Fig. 3A). 
GDC-0032 and radiation also slowed cell growth rates more than either treatment alone in 
PIK3CA-mutant cell lines Cal-33 and HSC-2, but had little effects in PTEN-altered cell 
lines UPCI-SCC-90 and UD-SCC-2 (Fig. 3B). The increased antitumor effects of combined 
radiation and GDC-0032 compared with either treatment alone were confirmed using 
Annexin staining in three additional cell lines bearing activating PIK3CA alterations 
(LB-771, SNU-1076, and HSC-2), whereas no significant additional activity was observed 
in cell lines with wild-type PIK3CA and/or inactivating PTEN alterations (HSC-3, UD-
SCC-2, HSC-4, and FaDu; Fig. 3C). Similar results were seen with the structurally unrelated 
p110α inhibitors BYL719 (Supplementary Fig. S2) and A66 (Supplementary Fig. S3), 
suggesting that GDC-0032 induces cell death following radiation primarily through p110α 
inhibition, rather than inhibition of other PI3K isoforms or off target enzymes.
Inhibition of other downstream PI3K components using an allosteric AKT inhibitor 
MK-2206 or the allosteric mTORC1 inhibitor RAD001 also increased radiation-induced 
apoptosis, albeit to a smaller degree than GDC-0032 (Fig. 3D). Similar results were 
observed with the PIK3CA-mutated cell line HSC-2, although RAD001 did not enhance 
radiation-induced apoptosis in this cell line (Supplementary Fig. S4).
The gold standard for assessing radiosensitization is clonogenic survival. Using this assay, 
Cal-33 cells pretreated with GDC-0032 had significantly decreased cell survival following 
radiation (Fig. 3E). Similar radiosensitization was seen when LB-771 cells were treated with 
GDC-0032 prior to radiation (Supplementary Fig. S5). However, GDC-0032 had no effect 
on the radiation response of HSC-3, a PIK3CA wild-type cell line resistant to single-agent 
GDC-0032 (Fig. 3D).
GDC-0032 delays the resolution of DNA double-strand breaks following radiation
PI3K signaling is a key regulator of the DNA damage response (15, 17–21, 39). Therefore, 
we decided to study whether the GDC-0032–dependent radiosensitization was at least in 
part attributable to impaired DDR under a state of PI3Kα inhibition. We quantified the 
amount of DNA double-strand breaks (DSB), as assessed by γH2AX foci, with and without 
GDC-0032 pretreatment in Cal-33 cells. Cells pretreated with GDC-0032 had significantly 
more γH2AX foci at 24 and 48 hours after irradiation than control-treated cells (Fig. 4A). 
This increase in DNA damage upon combination of radiation and GDC-0032 was 
accompanied by increased formation of p53-binding protein 1 (53BP1) foci, a mediator of 
the DSB repair downstream of γH2AX (Fig. 4B; ref. 40), and induction of PARP cleavage 
(Supplementary Fig. S6A). Consistent results were also observed in LB-771 cells 
(Supplementary Fig. S6B), supporting the notion that GDC-0032 impairs DSB repair in 
these cells following radiation.
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GDC-0032 enhances G2–M arrest following radiation
Ionizing radiation induces two molecularly distinct G2–M checkpoints (41). The first, 
known as the “early” G2–M checkpoint, consists of a transient, ATM-dependent mitotic 
block affecting cells in late G2 occurring within minutes of irradiation and can be assessed 
by the proportion of cells with phosphorylation of histone H3 (HH3) after irradiation (41). 
The second, more prolonged and known as the “late” G2–M checkpoint, is independent of 
ATM and results in an accumulation of cells with 4N DNA content (41). It is well accepted 
that the duration of the G2–M checkpoint reflects the number of unrepaired DSBs (42). 
Therefore, based on our results we hypothesized that GDC-0032 may alter the DNA 
damage–induced cell-cycle arrest that occurs following irradiation.
As single agent, treatment with GDC-0032 resulted in a mild increase in the proportion of 
cells in G1 over 72 hours, with a concomitant decrease in the G2 phase of the cell cycle (Fig. 
5A).
As expected, radiation induced both the early and late G2–M checkpoints, with a marked 
decrease in pHH3-positive cells (Supplementary Fig. S7) and an accumulation of cells with 
4N DNA content (Fig. 5B). However, by 48 hours after irradiation, the cell-cycle profile was 
nearly back to baseline. When we examined the impact of PI3Kα inhibition in this setting, 
we observed that, while treatment with GDC-0032 for 24 hours prior to irradiation did not 
significantly alter the cell-cycle profile of Cal-33 cells (Fig. 5B) or affect the early G2–M 
arrest as assessed by pHH3-positive cells (Supplementary Fig. S7), the proportion of cells 
with 4N DNA content at 24 and 48 hours after irradiation was considerably higher with than 
in control-treated cells. This suggests that the late G2–M arrest induced by radiation is 
enhanced by pharmacologic inhibition of PI3Kα (Fig. 5B).
Because the late G2–M checkpoint is known to be ATM independent, we investigated 
whether the enhanced late G2–M checkpoint induced by GDC-0032 could be abrogated by 
either inhibition of other known regulators of the G2–M cell-cycle progression, such as 
Wee1 and ATR. We found that although both Wee1 inhibition with AZD-1775 and ATR 
inhibition with VE-821 abrogated the early G2–M checkpoint following irradiation as 
assessed by pHH3 (Supplementary Figs. S8 and S9), only ATR inhibition with VE-821 
reversed the late G2–M arrest induced by the combination of GDC-0032 and radiation (Fig. 
5C and Supplementary Fig. S10). Taken together, these results indicate that GDC-0032 
enhances the late G2–M checkpoint induced by irradiation in an ATR-dependent fashion, 
resulting in increased DNA damage overtime.
GDC-0032 enhances the antitumor effects of radiotherapy in vivo
In order to test the ability of GDC-0032 to inhibit PI3K signaling in vivo, we treated nude 
mice implanted with subcutaneous Cal-33 xenografts with 5 mg/kg of GDC-0032 and 
harvested the tumors after 2, 6, and 24 hours of treatment. As expected, treatment with 
GDC-0032 resulted in nearly complete abrogation of AKT and PRAS40 phosphorylation, as 
well as decreased phosphorylation of 4EBP-1 and S6, at 2 hours after drug administration 
(Fig. 6A). However, by 6 hours after oral gavage, a rebound in phosphorylation of all of 
these PI3K targets was detected, probably a reflection of the short half-life of the compound.
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We next assessed the efficacy of combined PI3K inhibition and radiation. Mice received 
daily GDC-0032 throughout the experiment and 20 Gy in 5 daily fractions on days 2 to 6. 
Although treatment with either radiation or GDC-0032 alone resulted in tumor growth delay 
compared with vehicle-treated mice, only the combination of GDC-0032 and radiation 
resulted in durable tumor regressions (Fig. 6B). In fact, at the experiment endpoint (90 days 
of treatment), none of the tumors in the combined radiation and GDC-0032 arm had 
progressed in comparison to the start of the treatment. We also saw superior activity with 
transient administration of GDC-0032 during radiation in a HPV+ PIK3CAE545K patient-
derived xenograft model (Supplementary Fig. S11). These data also suggest that both 
mutations (E542K in the helical domain and H1047R in the kinase domain) are functionally 
active in HNSCC.
Moreover, our in vivo findings suggest that even a transient inhibition of the PI3K/AKT/
mTOR pathway (Fig. 6A) is sufficient to sensitize tumors to radiation, an observation with 
potential clinical implications.
Discussion
In this study, we determined that HNSCC cell lines containing activating PIK3CA 
alterations are significantly more sensitive to GDC-0032, a novel, potent inhibitor of PI3Kα, 
than cell lines without these alterations. This was consistent with previous studies of other 
PI3Kα inhibitors studied in breast cancer (36, 37, 43). Additionally, we found that PTEN 
aberrations were associated with resistance to GDC-0032, with 4 of the 6 most resistant 
HSNCC cell lines to this agent containing PTEN alterations, also consistent with previous 
data from our group (33).
Combining GDC-0032 and radiotherapy resulted in greater cell death than either treatment 
alone in cells with intrinsic sensitivity to GDC-0032. This translated in profound in vivo 
antitumor activity of the combination of GDC-0032 and radiation in PIKCA-mutant tumors.
The mechanisms underlying the strong antitumor efficacy of combined radiotherapy and 
PI3K inhibition in HNSCC are almost certainly multifactorial given the diverse phenotypic 
outputs induced by both radiation and PI3K signaling, including modulation of growth, 
survival, metabolic activity, angiogenesis, and immune response. However, we speculate that 
a major contributor to the efficacy of this combination is impaired DDR as a result of PI3K 
inhibition. Supporting this, we found that GDC-0032 pretreatment delays the resolution of 
deleterious DNA lesions following radiotherapy and prolongs the accumulation of cells in 
G2–M following irradiation in an ATR-dependent manner. It should also be noted that we 
observed strong in vivo effects of GDC-0032 and radiation despite the fact that inhibition of 
PI3K signaling was relatively transient. Although further studies may be needed with respect 
to the optimal timing and sequencing of GDC-0032 and radiation, our findings suggest that a 
strong pulsatile PI3K pathway inhibition would be sufficient to achieve effective 
radiosensitization.
Combining PI3K pathway inhibitors and radiation may be a particularly promising 
therapeutic strategy in HPV+ HNSCC for both biologic and clinical reasons. PIK3CA 
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mutations and amplifications are present in 22% to 37% and 20% to 25% of HPV+ tumors, 
respectively, an approximately 2- to 3-fold higher incidence over what is observed in HPV− 
tumors (11, 12). Furthermore, although PIK3CA mutations are found in the kinase domain, 
the helical domain, and other non-hotspot locations throughout the gene in HPV− HNSCC, 
almost all PIK3CA mutations in HPV+ HNSCC occur within the helical domain of p110α at 
either E542 or E545, suggesting that these specific helical domain codon changes convey a 
critical function in the pathogenesis of this disease (13). The limited PIK3CA mutation 
spectrum in HPV+ HNSCC also will likely simplify patient selection for clinical trials, 
obviating the complexity introduced by multiple mutations of unknown biochemical and 
phenotypic significance. Importantly, HPV+ tumors have increased radiosensitivity both 
preclinically and clinically in comparison to HPV− HNSCC (44, 45), and several clinical 
trials are currently under way to investigate strategies to de-escalate therapy without 
compromising cure rates. Thus, given the high prevalence of activating PIK3CA alterations 
in HPV+ HNSCC and the need to improve the toxicity profile of radiotherapy (by 
eliminating concomitant administration of chemotherapy), combining PI3K inhibitors with 
radiotherapy in select HPV+ patients may be a promising strategy for future clinical 
investigations. In fact, we are currently enrolling patients with HNSCC in a early phase 
clinical trial combining cetuximab, p110-alpha inhibition, and radiation.
In summary, we have demonstrated that specific PI3Kα inhibition is an effective strategy for 
HNSCC tumors harboring activating PIK3CA alterations in combination with radiotherapy. 
Given the importance of PI3K signaling both in the pathogenesis of HNSCC and in the 
response of cells to radiation, these types of strategies may represent an important step to 
reducing the toxicity of treatment by personalizing therapy while maintaining the excellent 
outcomes provided by cytotoxic chemoradiation.
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Translational Relevance
The recent identification of the landscape of genomic alterations occurring in head and 
neck tumors has resulted in new insights and the identification of potential new targets 
for therapy. Among them, PIK3CA, the gene encoding for the catalytic p110α subunit of 
PI3K, is one of the most frequently altered. Given that increased PI3K signaling is 
associated with radioresistance, there is a strong rationale to inhibit PI3K signaling as a 
strategy to enhance the therapeutic effects of radiotherapy. We, therefore, have 
investigated the efficacy of combining radiotherapy and GDC-0032, a potent inhibitor of 
PI3Kα currently in clinical development. We show the GDC-0032 radiosensitizes 
PIK3CA-activated head and neck squamous cell carcinoma (HNSCC) cell lines in vitro 
and impairs DNA damage repair. Further, combined GDC-0032 and radiation is more 
effective than either therapy alone in PIK3CA-mutated HNSCC xenograft models. These 
data suggest combining GDC-0032 and radiation warrants further clinical investigation in 
HNSCC.
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Figure 1. 
GDC-0032 has greater antiproliferative activity in cells containing activating PIK3CA 
alterations, whereas PTEN mutation or loss is associated with resistance to this agent. A, 26 
head and neck cancer cell lines were treated with GDC-0032 at varying concentrations, and 
antiproliferative IC50 values were calculated. B, IC50 values for GDC-0032, a β-sparing 
PI3K inhibitor, and GDC-0941, a pan-PI3K inhibitor, were compared for cell lines with 
either PIK3CA wild-type or PTEN mutation/loss versus cell lines with PIK3CA mutation/
amplification and wild-type PTEN.
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Figure 2. 
GDC-0032 is a more potent inhibitor of downstream AKT and mTOR signaling in head and 
neck cancer cell lines containing PIK3CA-activating alterations than in cell lines containing 
PTEN alterations. A, increasing doses of GDC-0032 were administered in serial dilution in 
Cal-33 (PIK3CA H1047R) or UD-SCC-2 (PTEN deletion), and cells were harvested after 4 
hours. B, time course following 100 nmol/L GDC-0032 in Cal-33, LB-771 (PIK3CA 
amplified), UPCI-SCC-90 (PTEN mutated), and UD-SCC-2.
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Figure 3. 
GDC-0032 enhances radiation-induced apoptosis and inhibits growth in head and neck 
cancer cell lines that are sensitive to its single-agent activity. A, Cal-33 (PIK3CAH1047R) 
cells were treated with DMSO or 100 nmol/L GDC-0032 for 24 hours, irradiated with 4 Gy, 
then analyzed for Annexin V–FITC and PI staining 72 hours later. B, Cal-33, HSC-2 
(PIK3CAH1047R), UD-SCC-2 (homozygous PTEN deletion), and UPCI-SCC-90 (PTEN 
mutant) were treated with either DMSO, 100 nmol/L GDC-0032, 4 Gy of radiation, or both. 
Cell proliferation was measured by counting cell numbers on the indicated days with a 
hemocytometer. C, various cell lines with or without PIK3CA or PTEN alterations were 
treated with 100 nmol/L for 24 hours, then irradiated with 4 Gy, and analyzed 72 hours later. 
D, Cal-33 cells were treated with either DMSO, 100 nmol/L GDC-0032, 2 mmol/
LMK-2206, 100 nmol/L RAD-001, or a combination of MK-2206 and RAD-001, then 
irradiated with 4 Gy after 24 hours. E, Cal-33 or HSC-3 (PIK3CA wild-type) were treated 
with 100 nmol/L GDC-0032 for 24 hours, then irradiated, then fixed and stained with crystal 
violet 10 days later. Surviving fractions were calculated based on the plating efficacy of the 
0-Gy plate for with DMSO or GDC-0032, respectively.
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Figure 4. 
GDC-0032 decreases clonogenicity and impairs DNA damage in Cal-33 following 
irradiation. Cal-33 cells were treated with DMSO or GDC-0032 for 24 hours, irradiated with 
4 Gy, and then assessed for (A) γH2AX foci or (B) 53BP1 foci. Each dot represents a single 
cell.
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Figure 5. 
GDC-0032 enhances the G2–M checkpoint following irradiation in an ATR-dependent 
manner. A, Cal-33 cells were treated with 100 nmol/L GDC-0032 and analyzed for DNA 
content at the given time points. B, Cal-33 cells were treated with DMSO or 100 nmol/L 
GDC-0032 for 24 hours, irradiated with 10 Gy, and analyzed for DNA content at the given 
time points after irradiation. C, Cal-33 cells were treated with GDC-0032, the ATR inhibitor 
VE-821, or both, and analyzed for DNA content following 10 Gy.
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Figure 6. 
GDC-0032 potently impairs PI3K signaling and enhances the efficacy of fractionated 
radiotherapy in vivo. A, four mice per time point were treated with 5 mg/kg GDC-0032, and 
tumors were harvested at the given time points. B, mice were treated with vehicle, 5 mg/kg 
GDC-0032, radiation with 20 Gy in 5 daily fractions, or both. GDC-0032 was started on day 
1, and radiation started on day 2. Daily administration of GDC-0032 was continued 
throughout the treatment.
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